Physician profile
Jeremy Sibal Aguinaldo
NPI 1235665225
$10,161.84
in general payments reported to CMS, 2019-2025
7 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 84% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $263 · 2021: $636 · 2022: $838 · 2023: $6,268 · 2024: $1,073 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,820 · Food and Beverage: $3,732 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,820.00 |
| Food and Beverage | $3,732.26 |
| Travel and Lodging | $872.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,921.15 | 2020-2025 | Biktarvy |
| Viiv Healthcare Company | $1,176.42 | 2020-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $451.62 | 2020-2025 | Pifeltro, Delstrigo, Isentress |
| Janssen Products, Lp | $242.04 | 2022-2023 | Symtuza |
| Theratechnologies INC. | $196.30 | 2020-2023 | Trogarzo, Egrifta, Egrifta Sv |
| Janssen Biotech, INC. | $157.69 | 2022-2023 | Symtuza |
| Medline Industries Lp | $16.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Aguinaldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.